Praluent alirocumab: Completed Phase III enrollment

The partners completed enrollment of 18,000 patients who have recently suffered an acute coronary syndrome (ACS) event in the double-blind, placebo-controlled, international Phase III ODYSSEY OUTCOMES trial evaluating 75 mg subcutaneous Praluent every 2 weeks plus background optimized lipid-lowering therapy. The partners have an SPA from FDA for the trial, which is part of the Phase III ODYSSEY program of Praluent. ...